The recent landscape of RSV vaccine research
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing recent developments in RSV prophylaxis without systematic review methodology or primary data
OpenAlex W4406242480 · doi:10.1177/25151355241310601
What was done
This paper provides a narrative overview of the current clinical and research landscape for respiratory syncytial virus (RSV) prevention. The review synthesizes the biology of key viral targets (glycoproteins G and F) and details recently licensed and late-stage pipeline prophylactic options, including monoclonal antibodies and maternal or adult vaccines.
What was found
The abstract reports no quantitative efficacy or safety statistics. Qualitatively, it highlights the emergence of the long-acting monoclonal antibody nirsevimab for infants, the licensing of three RSV vaccines (two protein subunit and one mRNA vaccine) for older adults (with one protein subunit vaccine also licensed for maternal immunization), and promising late-stage pipeline candidates including the extended half-life monoclonal antibody clesrovimab.
Why it matters
RSV causes substantial global morbidity and mortality in infants and older adults, historically with limited preventive options beyond palivizumab. The recent licensing and rollout of long-acting monoclonal antibodies and maternal and adult vaccines represent a fundamental shift in RSV prevention strategies.
Limits
The abstract does not report specific quantitative outcome measures, confidence intervals, or search methodology (it is a narrative overview rather than a systematic review). Issues regarding real-world cost-effectiveness, durability of protection, and equitable distribution to low- and middle-income countries remain active challenges not quantitatively evaluated here.
Cited by
- context The manufacturer of the RSV vaccine made 100 billion dollars from it.